Recursion Pharmaceuticals (RXRX) Shares Outstanding (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Shares Outstanding (Entity) came in at $530.6 million in Q1 2026, up 30.56% YoY from $406.4 million in Q1 2025, and little changed on a QoQ basis from $528.2 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Shares Outstanding (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Shares Outstanding (Entity) data on file, last reported at $530.6 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 30.56% year-over-year to $530.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $530.6 million (up 30.56% YoY) and the FY2025 annual result came in at $528.2 million, up 92.62% from the prior year.
- Shares Outstanding (Entity) steadied at $530.6 million in Q1 2026, from $528.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $530.6 million in Q1 2026 to a low of $171.1 million in Q1 2022.
- A 5-year average of $295.7 million and a median of $237.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 611.74% in 2022, down 3.22% in 2022.
- Tracing RXRX's Shares Outstanding (Entity) over 5 years: stood at $191.0 million in 2022, then rose by 22.64% to $234.3 million in 2023, then gained by 17.05% to $274.2 million in 2024, then jumped by 92.62% to $528.2 million in 2025, then grew by 0.46% to $530.6 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $530.6 million (Q1 2026), $528.2 million (Q4 2025), and $491.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 532.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 532.46 Mn |
| Mar 31, 2026 | 529.30 Mn |
| Dec 31, 2025 | 447.45 Mn |
| Sep 30, 2025 | 446.99 Mn |
| Jun 30, 2025 | 417.36 Mn |
| Mar 31, 2025 | 402.77 Mn |
| Dec 31, 2024 | 274.21 Mn |
| Sep 30, 2024 | 282.58 Mn |
| Jun 30, 2024 | 242.20 Mn |
| Mar 31, 2024 | 236.02 Mn |
| Dec 31, 2023 | 207.85 Mn |
| Sep 30, 2023 | 214.33 Mn |
| Jun 30, 2023 | 201.42 Mn |
| Mar 31, 2023 | 191.62 Mn |
| Dec 31, 2022 | 175.54 Mn |
| Sep 30, 2022 | 173.44 Mn |
| Jun 30, 2022 | 172.21 Mn |
| Mar 31, 2022 | 170.69 Mn |
| Dec 31, 2021 | 125.35 Mn |
| Sep 30, 2021 | 168.53 Mn |